Resources
ARC provides patients and healthcare professionals with the latest, up-to-date resources to
help improve treatment and care of patients with amyloidosis.

Booklets
Treatment Overview: Light Chain Amyloidosis
AL amyloidosis is a serious disease- progressive and fatal if left untreated. However, many patients benefit from current therapies, with their lives improved and prolonged, often for many years.
Read More
Booklets

Booklets
Disease Overview: Light Chain Amyloidosis
A diagnosis of light chain amyloidosis (AL amyloidosis) can be confusing and stressful, bringing up many feelings and questions. It is important to learn as much as possible about the disease, its treatment, and how it might affect you.
Read More
Booklets

Booklets
Treatment Overview: Hereditary Transthyretin Amyloidosis
We live in a time of rapid advances in genetic know-how
and pharmacological technologies. The pace of discovery is accelerating, driving the development of new therapies, with 3 newly approved treatments. The exact course of hATTR varies with each patient, but the outlook holds promise for all. This booklet is designed as a comprehensive guide to help you and your family navigate treatment resources and options that would be most effective for you.
Read More
Booklets

Booklets
Disease and Treatment Overview: Wild-Type Transthyretin Amyloidosis
Wild-type transthyretin amyloidosis (ATTRwt) is an age-related disease caused by transthyretin (TTR) proteins that become unstable, misfold, and build up in organs, impairing their function. It is a slowly progressive condition that affects older people, most often Caucasian men over 65 years of age. Heart disease is the hallmark of ATTRwt, but it is commonly preceded by other conditions, such as carpal tunnel syndrome or spinal stenosis.
Read More
Booklets

Booklets
Disease Overview: Hereditary Transthyretin Amyloidosis
Hereditary transthyretin amyloidosis (hATTR) is a rare, systemic disease passed down through families. Caused by genetic mutations in the transthyretin (TTR) gene, it leads to a buildup of abnormal proteins called amyloid in one or more organs and tissues, impairing their function. Left untreated, hATTR can cause life-threatening complications. Early diagnosis and treatment are critical to prevent or delay progression of hATTR.
Read More
Booklets

ARC Talks
Patients
Webinars
Patients
Webinars
Amyloid Neuropathy Burden and Mangement
In this ARC Talks webinar, Dr. Kelsey Barrell from the University of Utah explains what causes neuropathy and other neurological symptoms in amyloidosis patients and offers suggestions to help manage these symptoms.
Read More
ARC Talks

ARC Talks
Patients
Webinars
Patients
Webinars
GI Disturbances and Symptom Relief for Amyloidosis
Dr. John Clarke, a gastroenterologist and motility specialist with Stanford Medicine, covers everything that patients need to know about GI involvement and symptom management in amyloidosis, followed by a Q&A session.
Read More
ARC Talks

physicians
Webinars
Webinars
ARC Talks: Managing Amyloidosis during COVID-19 for Physicians
This physician webinar covers the treatment of amyloidosis patients during the COVID-19 pandemic. With guidelines from the International Society of Amyloidosis, high-risk patient considerations, an update on clinical trials, and policy changes, we cover everything HCPs need to know.
Read More
physicians